Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02392871 | Radiotherapy & Combi in Metastatic Melanoma(CombiRT) | completed | Phase 1 / Phase 2 | 10 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT05169957 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | completed | Phase 1 | 2 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04096638 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | invoX Pharma LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03875079 | A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 7 | Oct 3, 2024 | clinicaltrials |
| NCT03200847 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 1 / Phase 2 | 26 | University of Colorado, DenverOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | completed | Phase 1 / Phase 2 | 24 | Lokon Pharma ABINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05810740 | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | completed | Phase 1 | 37 | Pierre Fabre MedicamentINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03538314 | UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma | completed | Phase 1 | 30 | Ultimovacs ASAINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT00809588 | Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) | completed | Phase 1 | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05003622 | Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors(OCEANI) | completed | Phase 1 | 3 | Pierre Fabre MedicamentINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT03817125 | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention(MCGRAW) | completed | Phase 1 | 14 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02821000 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | completed | Phase 1 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 30, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | completed | Phase 1 / Phase 2 | 217 | AmgenINDUSTRY | 3 | May 14, 2024 | clinicaltrials |
| NCT01621490 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma(PD-1) | completed | Phase 1 | 170 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 23, 2024 | clinicaltrials |
| NCT04165967 | Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma(BaseTIL) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | completed | Phase 1 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02678741 | Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | completed | Phase 1 / Phase 2 | 26 | Elios Therapeutics, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02126579 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists(MEL60) | completed | Phase 1 / Phase 2 | 50 | Craig L Slingluff, JrOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma(Mel-65) | completed | Phase 1 / Phase 2 | 33 | Craig L Slingluff, JrOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03052127 | Study in Subjects With Small Primary Choroidal Melanoma | completed | Phase 1 / Phase 2 | 57 | Aura BiosciencesINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03123783 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 140 | Apexigen America, Inc.INDUSTRY | 2 | Dec 26, 2023 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | completed | Phase 1 | 43 | Apexigen America, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02729298 | First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | completed | Phase 1 | 177 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04904120 | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy(TIMAR1) | completed | Phase 1 | 7 | Perspective TherapeuticsINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | completed | Phase 1 / Phase 2 | 61 | Yale UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2024source: clinicaltrials